Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Stumbles, Actelion Rises In MS: Clinical Protocols Lost And Gained

Executive Summary

FDA casts a vote of confidence in Actelion's Phase III trial design for its oral multiple sclerosis candidate ponesimod, while Teva loses its special protocol assessment for laquinimod after dosing changes. Plus more regulatory clinical trial news in brief.

You may also be interested in...

Alcobra Ends Development Of MDX For Adult ADHD, Ponders Strategic Direction

Failing to meet the primary endpoint in its second Phase III study in adult ADHD, the Israeli firm confirms there is no path forward in that indication. Developing MDX for Fragile X syndrome and business development options are under consideration.

Multiple Sclerosis: Close To Being Conquered

The development of a plethora of new medicines for multiple sclerosis over the past 10 years is truly remarkable. As well as the dozen or so agents now available to treat relapsing MS, the first potential product for the poorly treated condition, primary progressive MS, is nearing the market.

Teva Faces Laquinimod Setback After High Dose Linked To CV Events

Teva will discontinue higher doses of laqunimod in two ongoing studies for multiple sclerosis after cardiovascular events were experienced in eight patients. Trials will continue with a lower dose.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts